These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Therapy-resistant hypertension--the value of aldosterone antagonists]. Quack I; Reincke M; Rump LC MMW Fortschr Med; 2007 Nov; 149(46):39-40. PubMed ID: 18069192 [TBL] [Abstract][Full Text] [Related]
24. Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice. Hashimoto A; Takeda Y; Karashima S; Kometani M; Aono D; Demura M; Higashitani T; Konishi S; Yoneda T; Takeda Y Hypertens Res; 2020 Oct; 43(10):1099-1104. PubMed ID: 32398797 [TBL] [Abstract][Full Text] [Related]
25. Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system. Viazzi F; Leoncini G; Pontremoli R High Blood Press Cardiovasc Prev; 2013 Dec; 20(4):273-82. PubMed ID: 24092648 [TBL] [Abstract][Full Text] [Related]
26. Salt, the renin-angiotensin-aldosterone system and resistant hypertension. Shimosawa T Hypertens Res; 2013 Aug; 36(8):657-60. PubMed ID: 23912973 [TBL] [Abstract][Full Text] [Related]
27. Revising the Roles of Aldosterone in Vascular Physiology and Pathophysiology: From Electocortin to Baxdrostat. Feldman RD; Sanjanwala R; Padwal R; Leung AA Can J Cardiol; 2023 Dec; 39(12):1808-1815. PubMed ID: 37734710 [TBL] [Abstract][Full Text] [Related]
29. Hypertension in chronic kidney disease-treatment standard 2023. Georgianos PI; Agarwal R Nephrol Dial Transplant; 2023 Nov; 38(12):2694-2703. PubMed ID: 37355779 [TBL] [Abstract][Full Text] [Related]
30. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension. Morimoto S; Ichihara A Hypertens Res; 2020 Aug; 43(8):744-753. PubMed ID: 32424201 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection. Lambers Heerspink HJ Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444 [TBL] [Abstract][Full Text] [Related]
32. Treatment of Resistant and Refractory Hypertension. Acelajado MC; Hughes ZH; Oparil S; Calhoun DA Circ Res; 2019 Mar; 124(7):1061-1070. PubMed ID: 30920924 [TBL] [Abstract][Full Text] [Related]
33. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases]. Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213 [TBL] [Abstract][Full Text] [Related]
39. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L Am J Hypertens; 2002 May; 15(5):389-93. PubMed ID: 12022239 [TBL] [Abstract][Full Text] [Related]
40. The role of aldosterone antagonists in the management of resistant hypertension. Nishizaka MK; Calhoun DA Curr Hypertens Rep; 2005 Oct; 7(5):343-7. PubMed ID: 16157075 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]